S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study.

Abstract

S-fluoxetine is the long-acting enantiomer of the racemic antidepressant serotonin reuptake inhibitor. Sixty-five patients needing migraine prophylaxis were recruited into a phase II, double-blind, placebo-controlled trial. After a 1-month placebo run-in, 53 patients met entry criteria with regard to attack frequency and were randomized, 27 to S-fluoxetine… (More)

Topics

Cite this paper

@article{Steiner1998SfluoxetineIT, title={S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study.}, author={Timm Steiner and F. Ahmed and Leslie J. Findley and Eve MacGregor and M. Wilkinson}, journal={Cephalalgia : an international journal of headache}, year={1998}, volume={18 5}, pages={283-6} }